In a study with propensity-score matching analysis, the authors found no significant difference in live birth or cumulative live birth rates between patients undergoing a GnRH-antagonist protocol with a freeze-all strategy and those using a long-acting GnRH agonist protocol in women with adenomyosis (42). This evidence concerns the gene GNRH1 and adenomyosis.